Lenvatinib, a VEGFR1-3, FGFR1-4, PDGFRα, c-Kit and RET inhibitor, is one of the six approved systemic therapies for hepatocellular carcinoma, the most common form of liver cancer [130,131]. This evidence concerns the gene KIT and hepatocellular carcinoma.